ES2440390B1 - Composiciones para el tratamiento del sobrepeso y de la obesidad - Google Patents
Composiciones para el tratamiento del sobrepeso y de la obesidad Download PDFInfo
- Publication number
- ES2440390B1 ES2440390B1 ES201231198A ES201231198A ES2440390B1 ES 2440390 B1 ES2440390 B1 ES 2440390B1 ES 201231198 A ES201231198 A ES 201231198A ES 201231198 A ES201231198 A ES 201231198A ES 2440390 B1 ES2440390 B1 ES 2440390B1
- Authority
- ES
- Spain
- Prior art keywords
- composition
- overweight
- obesity
- treatment
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 208000008589 Obesity Diseases 0.000 title abstract 2
- 206010033307 Overweight Diseases 0.000 title abstract 2
- 235000020824 obesity Nutrition 0.000 title abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 abstract 1
- 102000008186 Collagen Human genes 0.000 abstract 1
- 108010035532 Collagen Proteins 0.000 abstract 1
- 229920000045 Dermatan sulfate Polymers 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 208000004930 Fatty Liver Diseases 0.000 abstract 1
- 206010019708 Hepatic steatosis Diseases 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 229920001436 collagen Polymers 0.000 abstract 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 abstract 1
- 229940051593 dermatan sulfate Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000010706 fatty liver disease Diseases 0.000 abstract 1
- 229920002674 hyaluronan Polymers 0.000 abstract 1
- 229960003160 hyaluronic acid Drugs 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 231100000240 steatosis hepatitis Toxicity 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
La presente invención se refiere a una composición que comprende ácido hialurónico y sulfato de dermatano para su uso en el tratamiento o prevención de al menos una de las enfermedades que conforman el síndrome metabólico en un mamífero, seleccionada del grupo formado por sobrepeso, obesidad, resistencia a la insulina, diabetes tipo 2, hígado graso o dislipidemia. Además la composición puede contener hidrolizado de colágeno. La composición está en forma de composición farmacéutica.
Description
Claims (1)
-
imagen1
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES201231198A ES2440390B1 (es) | 2012-07-25 | 2012-07-25 | Composiciones para el tratamiento del sobrepeso y de la obesidad |
| ES13739437.5T ES2673099T3 (es) | 2012-07-25 | 2013-07-22 | Composiciones que comprenden ácido hialurónico y sulfato de dermatano para el tratamiento del sobrepeso y de la obesidad |
| PCT/EP2013/065384 WO2014016233A1 (en) | 2012-07-25 | 2013-07-22 | Compositions comprising hyaluronic acid and dermatan sulphate for the treatment of being overweight and obesity |
| CA2879645A CA2879645C (en) | 2012-07-25 | 2013-07-22 | Compositions comprising hyaluronic acid and dermatan sulphate for the treatment of being overweight and obesity |
| EP13739437.5A EP2884956B1 (en) | 2012-07-25 | 2013-07-22 | Compositions comprising hyaluronic acid and dermatan sulphate for the treatment of being overweight and obesity |
| US14/416,164 US20150182597A1 (en) | 2012-07-25 | 2013-07-22 | Compositions comprising hyaluronic acid and dermatan sulphate for the treatment of being overweight and obesity |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES201231198A ES2440390B1 (es) | 2012-07-25 | 2012-07-25 | Composiciones para el tratamiento del sobrepeso y de la obesidad |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2440390A1 ES2440390A1 (es) | 2014-01-28 |
| ES2440390B1 true ES2440390B1 (es) | 2014-11-13 |
Family
ID=48808358
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES201231198A Active ES2440390B1 (es) | 2012-07-25 | 2012-07-25 | Composiciones para el tratamiento del sobrepeso y de la obesidad |
| ES13739437.5T Active ES2673099T3 (es) | 2012-07-25 | 2013-07-22 | Composiciones que comprenden ácido hialurónico y sulfato de dermatano para el tratamiento del sobrepeso y de la obesidad |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13739437.5T Active ES2673099T3 (es) | 2012-07-25 | 2013-07-22 | Composiciones que comprenden ácido hialurónico y sulfato de dermatano para el tratamiento del sobrepeso y de la obesidad |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20150182597A1 (es) |
| EP (1) | EP2884956B1 (es) |
| CA (1) | CA2879645C (es) |
| ES (2) | ES2440390B1 (es) |
| WO (1) | WO2014016233A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2610014C1 (ru) * | 2016-03-23 | 2017-02-07 | Наталья Павловна Михайлова | Способ оздоровления |
| CN109924485A (zh) * | 2019-03-29 | 2019-06-25 | 华熙生物科技股份有限公司 | 一种含透明质酸的减肥保健食品及其制备方法 |
| FR3105729B1 (fr) * | 2019-12-31 | 2023-07-21 | Mrs Biotech | Composition pour la gestion du poids d’un sujet |
| AU2021246535A1 (en) * | 2020-04-03 | 2022-10-27 | International N&H Denmark Aps | Composition comprising bacterial strains for improving metabolic health |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4780414A (en) | 1985-01-18 | 1988-10-25 | Bio-Technology General Corp. | Method of producing high molecular weight sodium hyallronate by fermentation of streptococcus |
| IT1189085B (it) | 1986-03-25 | 1988-01-28 | Mediolanum Farmaceutici Srl | Processo per la preparazione di dermatan solfato ad alta purezza e composizioni farmaceutiche che lo contengono |
| JP2005046133A (ja) * | 2003-10-20 | 2005-02-24 | Medicaraise Corp | ヒアルロン酸とデルマタン硫酸を含有する健康食品 |
| ES2281265B1 (es) * | 2005-11-24 | 2008-08-16 | Bioiberica, S.A. | Composiciones para el tratamiento de la artrosis. |
| US7763594B2 (en) * | 2005-11-30 | 2010-07-27 | Bioiberica, S.A. | Compositions for the treatment of osteoarthritis and to nourish the synovial fluid |
| JP2008150326A (ja) * | 2006-12-18 | 2008-07-03 | Globe Company Inc | ドリンク剤 |
| JP2010059084A (ja) * | 2008-09-03 | 2010-03-18 | Q P Corp | 機能性食品及び医薬 |
| ES2528413T3 (es) * | 2010-04-12 | 2015-02-10 | Esm Holdings, Llc | Composición que comprende membrana de cáscara de huevo en polvo para su uso en el tratamiento de la diabetes mellitus |
-
2012
- 2012-07-25 ES ES201231198A patent/ES2440390B1/es active Active
-
2013
- 2013-07-22 US US14/416,164 patent/US20150182597A1/en not_active Abandoned
- 2013-07-22 EP EP13739437.5A patent/EP2884956B1/en active Active
- 2013-07-22 ES ES13739437.5T patent/ES2673099T3/es active Active
- 2013-07-22 CA CA2879645A patent/CA2879645C/en active Active
- 2013-07-22 WO PCT/EP2013/065384 patent/WO2014016233A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CA2879645A1 (en) | 2014-01-30 |
| EP2884956B1 (en) | 2018-03-21 |
| EP2884956A1 (en) | 2015-06-24 |
| WO2014016233A1 (en) | 2014-01-30 |
| US20150182597A1 (en) | 2015-07-02 |
| ES2440390A1 (es) | 2014-01-28 |
| CA2879645C (en) | 2020-07-28 |
| ES2673099T3 (es) | 2018-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021015060A2 (es) | Agonistas de glp-1r y usos de los mismos | |
| CL2014000801A1 (es) | Variante de factor 21 de crecimiento de fibroblasto humano (fgf21); composicion farmaceutica que lo comprende; y su uso para tratar diabetes tipo 2, obesidad, dislipidemia, sindrome metabolico o cualquier combinacion de los mismos. | |
| CL2013003025A1 (es) | Compuestos derivados de pirimidinas de diaminocarboxamida y diaminocarbonitrilo, como inhibidores de quinasa jnk; composicion farmaceutica; metodo de inhibicion in vitro; y su uso en el tratamiento o prevencion de trastornos fibroticos del higado, diabetes o sindrome metabolico conduciendo a trastornos fibroticos del higado. | |
| CL2012002606A1 (es) | Composicion farmaceutica que comprende (-)-carvona, (+)-carvona, trans-geraniol y al menos un componente elegido de aceites esenciales para uso en el tratamiento y prevencion de enfermedades virales. | |
| BR112012006692A2 (pt) | composição farmacêutica compreendendo ácido graxo de omega-3 e um derivado de hidróxi de uma estatina e métodos de uso das mesmas | |
| CL2013003372A1 (es) | Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes. | |
| CO6781465A2 (es) | Composición farmacéutica, métodos de tratamiento y usos de la misma | |
| CL2012003009A1 (es) | Acido3-(((3-butil-3-etil-(metiloxi)-1-1-dioxido-5-fenil-2,3,4,5-tetrahidro-1,4benxotiazepin-8-il)-metil)-amino)-pentanodioco; composicion farmaceutica que lo comprende; y su uso en un tastorno metabolico. pct. | |
| CR20170242A (es) | Benzamidas sustituidas copn 1,3-tiazol-2-ilo | |
| CU20140151A7 (es) | Composición farmacéutica útil en la prevención de un evento cardiovascular mayor | |
| BR112012032816A2 (pt) | composição farmacêutica de liberação controlada, e, métodos para reduzir o efeito alimentar de uma composição de liberação controlada, reduzir o período de tempo necessário para que seja alcançado um estado estável para a metformina, para aperfeiçoar a biodisponibilidade de uma forma de dosagem de liberação controlada de matriz | |
| CL2012003026A1 (es) | Composicion farmaceutica que comprende pioglitazona y linagliptina; procedimiento de preparacion; uso en el tratamiento de la diabetes tipo 2 o la obesidad. | |
| DK2838549T3 (da) | Farmaceutisk præparat til forebyggelse eller behandling af ikke-alkoholisk fedtleversygdom | |
| CL2012000620A1 (es) | Formulaciones farmaceuticas de un anticuerpo anti cd-20; uso de la formulacion para tratar enfermedad o trastorno que pueda corregirse mediante tratamiento con anticuerpo anti-cd20. | |
| DK2379063T3 (da) | Farmaceutisk præparat indeholdende én eller flere fumarsyreestere i en erosionsmatrix | |
| WO2012074930A3 (en) | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity | |
| BR112013029256A8 (pt) | combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2 | |
| BRPI0911612A2 (pt) | composições e métodos para o tratamento da esclerose múltipla. | |
| BR112015011430A2 (pt) | composição para liberação imediata e prolongada | |
| BR112014005025A2 (pt) | composição farmacêutica para uso no tratamento de uma doença neurodegenerativa | |
| CL2014000050A1 (es) | Composicion farmaceutica en forma de solucion que comprende apomorfina, un codisolvente micible en agua, un antioxidante y agua, en la que el ph es superior a 4; procedimiento para fabricarla; y su uso como solucion inyectable en el tratamiento de la enfermedad de parkinson. | |
| BR112015018259A2 (pt) | Redução de resposta pró-inflamatória | |
| ES2445846R1 (es) | Una composición de combinación farmacéutica y su uso para preparar un medicamento destinado al tatamiento de la diabetes de tipo l y los trastornos metabólicos | |
| ES2440390B1 (es) | Composiciones para el tratamiento del sobrepeso y de la obesidad | |
| BRPI1009781A2 (pt) | compostos para o tratamento de distúrbios metabólicos, composição farmacêutica que os compreende e uso dos mesmos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 2440390 Country of ref document: ES Kind code of ref document: B1 Effective date: 20141113 |